1. Epigenetics
  2. DNA Methyltransferase
  3. Levetiracetam

Levetiracetam (Synonyms: UCB L059)

Cat. No.: HY-B0106 Purity: 99.99%
Handling Instructions

Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent.

For research use only. We do not sell to patients.

Levetiracetam Chemical Structure

Levetiracetam Chemical Structure

CAS No. : 102767-28-2

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 79 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 79 In-stock
Estimated Time of Arrival: December 31
Solid
50 mg USD 72 In-stock
Estimated Time of Arrival: December 31
100 mg USD 120 In-stock
Estimated Time of Arrival: December 31
500 mg USD 312 In-stock
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Levetiracetam:

Top Publications Citing Use of Products

View All DNA Methyltransferase Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent[1][2].

IC50 & Target

M2 mAChR[1]

In Vitro

Levetiracetam increases the transcription of HDACs and recruits corepressor complex on O6-Methylguanine-DNA-methyltransferase (MGMT) promoter, thus silencing its activity[1].
Levetiracetam sensitizes (40 μg/mL) glioblastoma multiforme stem-like cells (GSCs) to Temozolomide (250 µM) treatment[1].
MGMT expression is downregulated in GCSCs treated with Levetiracetam (40 μg/mL)[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: GCSC neurospheres
Concentration: 40 μg/mL
Incubation Time: 48 hours
Result: Slight antitumor effect exerted by the treatment with Temozolomide (250 µM) or Levetiracetam (40 μg/mL) alone was strongly enhanced when Temozolomide and Levetiracetam were added in combination.

Western Blot Analysis[1]

Cell Line: Glioblastoma multiforme stem-like cells (GSCs)
Concentration: 40 μg/mL
Incubation Time: 48 hours
Result: A high level of MGMT expression in untreated GCSCs; this expression was slightly decreased after treatment with Temozolomide (250 µM) and Levetiracetam singularly but it was dramatically decreased after the combined treatment with Temozolomide and Levetiracetam.
In Vivo

Levetiracetam (10, 25, or 50 mg/kg) suppresses behavioral and electrographic seizure activity during neonatal hypoxia[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Long-Evans rats[2]
Dosage: 10, 25, or 50 mg/kg
Administration: Intraperitoneal injection 60 min before hypoxia.
Result: Treatment resulted in a significant decrease in hypoxic seizure (HS) duration at 25 mg/kg and at 50 mg/kg. Anticonvulsant activity was maximal at 50 mg/kg, at which HSs were reduced by 63.6%.
Clinical Trial
Molecular Weight

170.21

Formula

C₈H₁₄N₂O₂

CAS No.
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : ≥ 85 mg/mL (499.38 mM)

DMSO : ≥ 85 mg/mL (499.38 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 5.8751 mL 29.3755 mL 58.7510 mL
5 mM 1.1750 mL 5.8751 mL 11.7502 mL
10 mM 0.5875 mL 2.9375 mL 5.8751 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (587.51 mM); Clear solution; Need ultrasonic

  • 2.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.17 mg/mL (12.75 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.17 mg/mL (12.75 mM); Clear solution

  • 4.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.17 mg/mL (12.75 mM); Clear solution

*All of the co-solvents are provided by MCE.
References

Purity: 99.99%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Levetiracetam
Cat. No.:
HY-B0106
Quantity:
MCE Japan Authorized Agent: